Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 8/20 | 0.41 |
| ▸ | HPGD | P15428 | 3/20 | 0.41 |
| ▸ | MAPT | P10636 | 2/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.41 |
| ▸ | MEN1 | O00255 | 2/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.41 |
| ▸ | RAB9A | P51151 | 2/20 | 0.41 |
| ▸ | NPC1 | O15118 | 1/20 | 0.41 |
| ▸ | PKM | P14618 | 1/20 | 0.41 |
| ▸ | SMPD1 | P17405 | 2/20 | 0.39 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.39 |
| ▸ | GAA | P10253 | 2/20 | 0.39 |
| ▸ | RECQL | P46063 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | ELANE | P08246 | 1/20 | 0.37 |
| ▸ | CES2 | O00748 | 1/20 | 0.37 |
| ▸ | CES1 | P23141 | 1/20 | 0.37 |
| ▸ | CCNA2 | P20248 | 1/20 | 0.37 |
| ▸ | CDK2 | P24941 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3853732 | 0.88 | KDM4E (0.44) | ALDH1A1HPGDMAPTSMN1; SMN2MEN1 | |
| SCHEMBL10925378 | 0.84 | KMT2A (0.44) | ALDH1A1HPGDMAPTSMN1; SMN2MEN1 | |
| SCHEMBL4781509 | 0.83 | ALDH1A1 (0.43) | ALDH1A1HPGDMAPTSMN1; SMN2MEN1 | |
| SCHEMBL10926602 | 0.82 | NPC1 (0.56) | ALDH1A1MAPTSMN1; SMN2MEN1KMT2A | |
| SCHEMBL10925296 | 0.81 | ATM (0.39) | ALDH1A1HPGDMAPTSMN1; SMN2MEN1 | |
| SCHEMBL1324894 | 0.78 | POLB (0.48) | ALDH1A1HPGDMAPTSMN1; SMN2MEN1 | |
| SCHEMBL15332383 | 0.77 | APOBEC3A (0.35) | ALDH1A1HPGDMAPTSMN1; SMN2MEN1 | |
| SCHEMBL10926015 | 0.77 | NPC1 (0.63) | ALDH1A1MAPTSMN1; SMN2MEN1KMT2A | |
| SCHEMBL8114735 | 0.73 | HDAC6 (0.66) | ALDH1A1HPGDMAPTSMN1; SMN2MEN1 | |
| SCHEMBL3852258 | 0.73 | APOBEC3A (0.35) | ALDH1A1HPGDMAPTSMN1; SMN2MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7576220-B2 | Method of producing 1,2,4-oxadiazole derivatives | RIKKYO GAKUIN (JP) | 2009-08-18 | — | — | US | claimed |
| US-20080086009-A1 | Method of producing 1,2,4-oxadiazole derivatives | RIKKYO GAKUIN (JP) | 2008-04-10 | — | — | US | claimed |
| US-8609696-B2 | Serotonin 5-HT2B receptor inhibitors | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2013-12-17 | — | — | US | disclosed |
| US-20110269742-A1 | Serotonin 5-HT2B Receptor Inhibitors | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2011-11-03 | — | — | US | disclosed |
| US-7576220-B2 | Method of producing 1,2,4-oxadiazole derivatives | RIKKYO GAKUIN (JP) | 2009-08-18 | — | — | US | disclosed |
| US-20080086009-A1 | Method of producing 1,2,4-oxadiazole derivatives | RIKKYO GAKUIN (JP) | 2008-04-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110269742-A1 | Serotonin 5-HT2B Receptor Inhibitors | HTR2B, HTR1B, HTR3B | ALDH1A1 747/4885HPGD 675/4885MAPT 3385/4885 |
| US-20080086009-A1 | Method of producing 1,2,4-oxadiazole derivatives | NOS1, NOS2, NOS3 | ALDH1A1 23/4885HPGD 309/4885MAPT 4357/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.